Circulating microRNA-122, microRNA-126-3p and microRNA-146a are associated with inflammation in patients with pre-diabetes and type 2 diabetes mellitus: A case control study

Fahime Zeinali1,2*, Seyed Mohsen Aghaei Zarch3*, Alireza Jahan-Mihan4, Seyed Mehdi Kalantar3,5, Mohammad Yahdi Vahidi Mehrjardi6, Hossein Fallahzadeh7, Mahdieh Hosseinzadeh1,2, Masoud Rahmanian6, Hassan Mozaffari-Khosravi1,2,6*  
1 Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, 2 Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, 3 Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, 4 Department of Nutrition and Dietetics, University of North Florida, Jacksonville, FL, United States of America, 5 Yazd Clinical and Research Center of Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, 6 Yazd Diabetic Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, 7 Department of Biostatistics and Epidemiology, Research Center of Prevention and Epidemiology of Non-Communicable Disease, School of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran  
* These authors contributed equally to this work.  
* mozaffari.kh@gmail.com  

Abstract  
The prevalence of type 2 diabetes mellitus (T2DM) is increasing dramatically worldwide. Dysregulation of microRNA (miRNA) as key regulators of gene expression, has been reported in numerous diseases including diabetes. The aim of this study was to investigate the expression levels of miRNA-122, miRNA-126-3p and miRNA-146a in diabetic and pre-diabetic patients and in healthy individuals, and to determine whether the changes in the level of these miRNAs are reliable biomarkers in diagnosis, prognosis, and pathogenesis of T2DM. Additionally, we examined the relationship between miRNA levels and plasma concentrations of inflammatory factors including tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) as well as insulin resistance. In this case-control study, participants (n = 90) were allocated to three groups (n = 30/group): T2DM, pre-diabetes and healthy individuals as control (males and females, age: 25–65, body mass index: 25–35). Expression of miRNA was determined by real-time polymerase chain reaction (RT-PCR). Furthermore, plasma concentrations of TNF-α, IL-6 and fasting insulin were measured by enzyme-linked immunosorbent assay. Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as an indicator of insulin resistance. In this case-control study, participants (n = 90) were allocated to three groups (n = 30/group): T2DM, pre-diabetes and healthy individuals as control (males and females, age: 25–65, body mass index: 25–35). Expression of miRNA was determined by real-time polymerase chain reaction (RT-PCR). Furthermore, plasma concentrations of TNF-α, IL-6 and fasting insulin were measured by enzyme-linked immunosorbent assay. Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as an indicator of insulin resistance.
MiRNA-122, miRNA-126, miRNA-146a are associated with inflammation in pre-diabetes and type 2 diabetes mellitus

http://www.ssu.ac.ir/ and Iran’s National Science Foundation (INSF) (grant number: 96012141) (Email: medicine@insf.org) https://rtms.insf.org/. H.MK. received the grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: ELISA, Enzyme-linked immunosor bent assay; PCR, Polymerase chain reaction; HOMA-IR, Homeostatic model assessment for insulin resistance; TNF-α, Tumor necrosis factor alpha; miRNA, MicroRNA; EDTA, Ethylene diamine tetra acetic acid; T2DM, Type 2 diabetes mellitus; HbA1c, Glycosylated hemoglobin type A1c; qPCR, Quantitative polymerase chain reaction; UTR, Untranslated region; IL6, Interleukin 6; IR, Insulin resistance; ROS, Reactive oxygen species; JNK, c-Jun N-terminal kinases; NF-kB, Nuclear factor kappa-light-chain-enhancer of activated B cells; MAPK, Mitogen-activated protein kinase; FPG, Fasting plasma glucose.

resistance (r = -0.67 and r = -0.78 respectively) (all p<0.05). Findings of this study suggest the miRNAs can potentially contribute to the pathogenesis of T2DM. Further studies are required to examine the reproducibility of these findings.

Introduction

Diabetes mellitus, as a chronic metabolic disease, is characterized by hyperglycemia due to inadequate insulin production by pancreatic beta cells (T1DM) or insulin resistance (inability to respond properly to insulin)(T2DM) [1, 2]. Type 2 diabetes mellitus (T2DM) is known as a risk factor for a variety of micro- and macro-vascular complications including cardiomyopathy, nephropathy and amputation that increases the rate of mortality in T2DM patients [3]. Fasting blood glucose (FBG), hemoglobin A1c (HbA1c), oral glucose tolerance test (OGTT) and homeostatic model assessment for insulin resistance (HOMA-IR) are among the most common tests that have been used for screening and diagnosis of diabetes mellitus. However, these parameters can predict the development of T2DM only when disease manifestation in patients have already caused metabolic alterations. In this regard, biomarkers for early detection of T2DM and identification of individuals at risk of developing diabetic complications could potentially complement the use of these parameters [4, 5]. Identifying biological predictors involved in T2DM can disclose new biological pathways involved in this disease as well as early detection, and prognosis of this disease [6].

MicroRNAs (miRNAs) are conserved non-coding and intracellular molecules that inhibit translation of their target molecules by binding to the 3’-UTR region of the target molecules [7]. The miRNAs are synthesized by RNA POL II in the nucleus, where they are also processed by RNase III Dorsha as well as DGC88 to the pre-miRNA molecules (70 to 100 nucleotides long) that are transferred to cytoplasm by exportin 5 (XPO5). In the cytoplasm, pre-miRNA is processed by Dicer, and finally a mature miRNA molecule with 20 to 25 nucleotides is produced [8]. Recently, it has been shown that these molecules are involved in pathological processes such as T2DM and cancer [6, 9, 10]. MiRNAs are stable molecules present in tissues and a number of body fluids such as blood where they are protected from endogenous ribonuclease (RNase) activity [11]. Access to miRNA is possible with non-invasive methods and can be tested by specific and sensitive methods such as quantitative polymerase chain reaction (qPCR) [12].

Chronic inflammation in insulin-responsive tissues is one of the most important causes of insulin resistance consistent with elevated reactive oxygen species (ROS) levels leading to the activation of stress-related signaling pathways which in turn activates protein kinases such as c-Jun N-terminal kinases (JNKs), protein kinase C (PKC), glycogen synthase kinase 3 (GSK-3), nuclear factor kappa B (NF-kB) and P38 mitogen-activated protein kinase (MAPK) signaling, which plays an important role in insulin resistance [13, 14]. There is an increasing evidence that miRNAs are major players in inflammatory processes and immune responses.

MiRNA-122 is mainly expressed in liver and its function in lipid accumulation has been verified. In one study, enhanced miRNA-122 expression contributed to the inflammation resolution via TNF-α and IL-6 suppression in a human liver organoid model [15].

In human genome, miRNA -126 is found on chromosome 9 within intron 7 of the EGFL7 gene [16]. It serves as an angio-miRNA and is mainly expressed in endothelial cells [17]. MiRNA-126 by targeting Spred1 (Sprouty-related EVH1 domain containing 1) can play a crucial role in inflammation resolution. Elevated expression of Spred1 via suppressing miRNA-126 expression in diabetic patients would promote IL-6, TNF-α and ROS production and results in endothelial cell dysfunction [18].
MiRNA-146a is located on long arm of chromosome 5 [19]. Bhatt et al. found that miRNA-146a has a protective role against inflammation by targeting the genes involved in the inflammation process in rats. In addition, the absence of protective mechanisms in miRNA-146a-/- mice exacerbates diabetic nephropathy. These results suggest miRNA-146a as one of the latest anti-inflammatory miRNAs [20]. In addition, Chen et al. [21] found that inflammatory cytokines secretion is significantly reduced from miRNA-146a transfected dendritic cells. On the other hand, the role of two human microorganisms known as herpes simplex virus-1 (HSV-1) as well as Bacteroides fragilis in the activation of NF-κB (p50/p65) and the up-regulation of miRNA-146a was suggested by Lukiw et al. (2008). These microbiota contribute to the inflammation-mediated amyloidogenic neuropathology of Alzheimer’s disease (AD) [22]. These conflicting studies underscore the fact that further studies are needed to determine the role of miRNA-146a in inflammatory signaling in AD and its potential underlying mechanisms.

Therefore, the primary goal of this study was to examine the expression levels of miRNA-122, miRNA-126-3p and miRNA-146a in T2DM and in pre-diabetic patients and in healthy individuals and determine whether they can be utilized as reliable biomarkers for early diagnosis and prevention of T2DM complications. Pre-diabetic and healthy individuals to determine their implication as novel biomarkers in early diagnosis of T2DM. The second goal of this study was to investigate the relationship between miRNAs and inflammatory factors such as TNF-α, IL-6 and insulin resistance to understand the role of miRNAs in the development of T2DM.

**Materials and methods**

**Sample size**

The required sample size was calculated according to a previous study [23] and based on Ct changes of miRNA-146a as the key factor for sample size calculation. The mean change in Ct was considered as the effect size. A mean difference in serum miRNA-146a level of 0.5 between the two groups (patients with T2D and healthy individuals) was aimed to be detected for a specified α of 0.05 and a study power of 80%. Based on the proposed formula for case-control studies [24], we reached a sample size of 30 participants in each group.

**Subjects**

Participants (n = 90) were patients with either T2DM, pre-diabetic patients, or healthy individuals (n = 30/group). The classification was based on guidelines provided by American Diabetes Association (ADA) as follows [25]:

- Healthy subjects: fasting plasma glucose (FPG) < 100 mg/dL (< 5.6 mmol/L) and HbA1c < 5.7% (< 39 mmol/mol)
- Prediabetic subjects: FPG 100–125 mg/dL (5.6–6.9 mmol/L) and/or HbA1c: 5.7–6.4% (39–47 mmol/mol)
- Controlled diabetic subjects: FPG ≥ 126 mg/dL (7.0 mmol/L) and/or HbA1c ≥ 6.5% (48 mmol/mol)

The inclusion criteria: 1) age: 25 to 65 years; 2) having no micro-vascular and macro-vascular complications (e.g. retinopathy, nephropathy, amputation) 3) lack of infectious and coronary artery disease; 4) Body mass index (BMI) 25–35 kg/m²; 5) No smoking.

Healthy individuals were gender and age-matched with T2DM and prediabetes groups.

**Blood sampling**

Fasting blood sample (10 ml) was taken from participants in the medical diagnostic laboratory of the Yazd Diabetes Research Center: 4 ml in tubes containing ethylene diamine tetra acetate...
acid (EDTA) for RNA extraction, 2 ml in a CBC tube containing EDTA to measure HbA1c and 4 ml in a test tube containing a clot activator for serum separation. dx.doi.org/10.17504/protocols.io.bax5ifq6 [PROTOCOL DOI].

Biochemical measurements

Serum lipid profiles and fasting blood glucose (Pars Azmoon Kit) were measured by using an auto-analyzer (alpha-classical, Isfahan, Iran). The enzyme-linked immunosorbent assay (ELISA) was used to determine serum levels of fasting insulin (Monobind, Lake Forest, CA, USA. Cat# 5825-300A), TNF-α (Diaclone, Besancon, France. Cat# 950.090.096) and IL-6 (Diaclone, Besancon, France. Cat# 950.030.096). Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated by the following equation: (fasting insulin (IU/ml) × fasting glucose (mmol/l))/22.5) [26].

RNA extraction and quantitative real time PCR

Total RNA containing long RNA and small RNA were extracted by GeneAll Kit (General Biosystems, Seoul, Korea. Cat# 315–150) according to manufacturer’s instructions. The quality of RNA was assessed using Thermo Fisher Scientific nanodrop. The absorbance was measured at 260 and 280 nm wavelengths, and the RNA concentration was measured in each specimen. The A260/A280 provides a rough indication of purity of nucleic acid (RNA) [27]. Science the ratio of absorbance at 260 and 280 nm were in the range of 1.8 to 2.2, we found out the purity of the isolated RNA. Then cDNA synthesis was performed by Stem-loop quantitative reverse transcription PCR (RT-qPCR). (Bonyakhteh, Tehran, Iran. Cat# BON209001). Finally, BONmiR QPCR Kit (Bonyakhteh, Tehran, Iran. Cat# BON209002) was used to investigate the miRNAs gene expression by Rotor Gene 6000 machine (Corbett, Concorde, NSW, Australia). The relative amounts of miRNAs (fold changes) were determined based on 2^{-\Delta\Delta Ct} (Livak) method. The changes in threshold cycle (\Delta Ct) were calculated by subtracting the Ct values of the reference SNORD from the Ct values of the target miRNAs (miRNA-122, miRNA-126-5p and miRNA-146a). \Delta\Delta Ct was then calculated by subtracting the average \Delta Ct values of the controls (healthy individuals) from the average \Delta Ct values of the cases (pre-diabetes or diabetes). \Delta\Delta Ct = (Ct_{miRNA} – Ct_{SNORD})_{T2DM or pre-diabetes} – (Ct_{miRNA} – Ct_{SNORD})_{healthy individuals} [23, 28, 29].

To measure the expression levels of miRNA-122, miRNA-126-5p and miRNA-146a, qPCR in the whole blood sample of T2DM, pre-diabetic and control group was applied. SNORD was used as an internal control gene. Amplification efficiency has long been a predominant aspect of implementing real-time qPCR and plays a crucial role in the reliability as well accuracy. Therefore, amplification efficiency is calculated from the slope of the log-linear region, similar to that conducted for standard curves. Primer sets used in our study lie between 90–110% efficient [30].

Bioinformatics analysis

Bioinformatics softwares such as miRDB (www.mirdb.org), miRanda (http://www.microrna.org/microrna/) and TargetScan (http://www.targetscan.org) were used to identify the potential targets (mRNAs) of miRNA-122, miRNA-126-3p and miRNA-146a.

Ethical considerations

This study was approved by the Ethical Committee of Shahid Sadoughi University of Medical Sciences (IR.SSU.SPH.REC.1396.172). Written consent was obtained from patients who decided to join the project.
Statistical analysis

All data are presented as mean ± standard deviation (SD). The data of this research were analyzed by Graph Pad Prism 7 software (Graph Pad, San Diego, CA, USA). The data normalization was performed using the Smirnov-Kolmogorov (K-S) test. The statistical significance of miRNA-122, miRNA-126-3p and miRNA-146a expression levels between T2DM, pre-diabetic and control group were investigated by one-way ANOVA. If significant, the Tukey’s Post Hoc test was used to compare means among groups. The association between inflammatory parameters as well as insulin resistance with miRNA-122, miRNA-126-3p and miRNA-146a expression levels were determined by Pearson’s correlation coefficient. P-values less than 0.05 were considered statistically significant.

Results

The characteristics of participants are summarized in Table 1. Oligonucleotide sequences for RT-PCR analysis are shown in Table 2.

MiRNA-122 expression levels in T2DM, pre-diabetic and healthy control group

The expression levels of miRNA-122 in pre-diabetic (fold change = 3.92 ± 0.78) as well as T2DM individuals (fold change = 9.04 ± 1.17) were considerably up-regulated compared to healthy control group (fold change 1.05 ± 0.34) (Both p < 0.001). Furthermore, the expression level of miRNA-122 was higher in T2DM individuals compared to pre-diabetic group (p < 0.001) (Fig 1A).

MiRNA-126-3p expression levels in T2DM, pre-diabetic and healthy control group

MiRNA-126-3p expression levels were decreased in patients with T2DM (fold change = 0.09 ± 0.09) compared to the control group (fold change = 1.07 ± 0.40) (p < 0.001). Additionally, significant reduction was found in the pre-diabetic group (fold change = 0.29 ± 0.12)

Table 1. Biochemical parameters of the studied groups.

|                              | Healthy (n = 30) | Pre-diabetes (n = 30) | T2DM (n = 30) | P-value |
|------------------------------|-----------------|-----------------------|--------------|---------|
| FPG (mg/dl)                  | 94.37 ± 7.05    | 116.7 ± 6.51          | 138.2 ± 7.02 | <0.001  |
| HbA1c (%)                    | 4.54 ± 0.2      | 5.9 ± 0.2             | 7.29 ± 1.22  | <0.001  |
| Triglycerides (mg/dl)        | 167.2 ± 87.6    | 178.6 ± 87.85         | 256 ± 385.5  | 0.44    |
| Cholesterol (mg/dl)          | 162.2 ± 27.94   | 181.4 ± 44.36         | 199.1 ± 79.24| 0.15    |
| HDL (mg/dl)                  | 39.82 ± 11.93   | 35.42 ± 12.07         | 34.07 ± 5.782| 0.17    |
| Fasting Insulin (μIU/mL)     | 10.47±0.81      | 11.26±0.98            | 12.06±1.29   | <0.001  |
| HOMA-IR                      | 2.44±0.27       | 3.25±0.40             | 4.12±0.57    | <0.001  |
| TNF-α (pg/ml)                | 9.26±0.4        | 7.32±0.34             | 9.26±0.99    | 0.001   |
| IL-6 (pg/ml)                 | 3.28±0.15       | 2.86±0.05             | 3.28±0.19    | 0.001   |
| Ct miRNA-122                 | 5.3±0.47        | 3.35±0.29             | 2.13±0.19    | <0.001  |
| Ct miRNA-126-3p              | 2.36±0.58       | 4.24±0.62             | 6.26±1.3     | <0.001  |
| Ct miRNA-146a                | 2.49±0.48       | 2.96±0.39             | 5.89±0.98    | <0.001  |
compared to the control group (P<0.001). Moreover, the expression level of miRNA-126-3p was lower in T2DM individuals compared to pre-diabetic group (P<0.001) (Fig 1B).

**MiRNA-146a expression levels in T2DM, pre-diabetic and healthy control group**

The expression levels of miRNA-146a in T2DM individuals (fold change = 0.11 ± 0.09) as well as pre-diabetic (fold change = 0.75 ± 0.22) were considerably down-regulated compared to control (fold change 1.05 ± 0.33) (Both P<0.001). Furthermore, miRNA-146a expression level was lower in T2DM patients compared to pre-diabetic individuals (P<0.001) (Fig 1C).

**Identification key target gene**

We identified that TNF-α and IL-6 are the potential targets of miRNA-126-3p and miRNA-146a. The results suggested that there is a miRNA-146a binding site in IL-6 and TNF-α genes. MiRNA-122 binding sites were not found in TNF-α, IL-6 genes. Other important targets are displayed in Table 3.

**Association of inflammatory factors with circulating miRNA-122, miRNA-126-3p and miRNA-146a**

A positive association between miRNA-122 and IL-6 (r = 0.83, P<0.001), TNF-α (r = 0.82, P<0.001) were observed. On the other hand, negative association were detected between miRNA-126-3p and miRNA-146a expression levels and IL-6 (r = -0.65 and r = -0.78 respectively) and TNF-α (r = -0.7 and r = -0.82 respectively) concentration (All P<0.001) (Table 4).

---

**Table 2. Oligonucleotide primers.**

| Gene       | Sequence                           |
|------------|------------------------------------|
| MiRNA-122  | Forward: GGAGTGTGACATGGTGTT         |
| MiRNA-126-3p| Forward: GCCGTCGTAAGGTAGTAAT       |
| MiRNA-146a | Forward: GAAGGTGAGAAGCTGAAT       |
| SNORD      | Forward: GAACGATACAGAGAGATTAG      |

https://doi.org/10.1371/journal.pone.0251697.t002

---

![Fig 1. Comparison of expression levels of miRNA-122, miRNA-126-3p and miRNA-146a in T2DM (n = 30), pre-diabetic (n = 30) and control group (n = 30). A) Comparison of miRNA-122 expression level in 3 groups. B) Comparison of miRNA-126-3p expression level in 3 groups. C) Comparison of miRNA-146a expression level in 3 groups.](https://doi.org/10.1371/journal.pone.0251697.g001)
Association of insulin resistance with circulating miRNA-122, miRNA-126-3p and miRNA-146a

A positive correlation between miRNA-122 and insulin resistance (r = 0.8, p < 0.0001) was observed. Conversely negative correlation between miRNA-126-3p and miRNA-146a expression levels and insulin resistance (r = -0.67 and r = -0.78 respectively) were observed (P < 0.001) (Table 4).

Discussion

In this population-based, case-control study, we found a significant direct association between inflammatory cytokines including IL-6 and TNF-α as well as HOMA-IR with gene expression levels of pro-inflammatory miRNA-122 in general population. This significant association was
reversed in terms of two other anti-inflammatory miRNAs. Such that both miRNA-126-3p and miRNA-146a gene expressions were inversely associated with IL-6 and TNF-α serum concentrations; and HOMA-IR in our study population. To the best of our knowledge, this study is the first observational study examining the association between inflammation-related miRNAs with serum levels of inflammatory cytokines, in particular IL-6 and TNF-α; and HOMA-IR in T2DM patients. Evaluation of these relations is more relevant to develop diagnostic and therapeutic methods of chronic diseases including T2DM [31]. Growing evidence has shown a link between specific miRNAs and chronic inflammation in T2DM. The inflammatory state has crucial role in hyperglycemia insulin resistance of these patients [32]. Increasing levels of inflammatory cytokines specially TNF-α are at the heart of inflammatory cascades linked to insulin resistance [33], as we observed in present study in which levels of TNF-α and IL-6 were significantly higher in diabetic and pre-diabetic patients compared to healthy controls. Our findings were in line with other reports that have shown the elevated levels of TNF-α in serum of T2DM patients [34–36]. Similarly, in terms of IL-6, increased serum concentrations of IL-6 were seen in diabetic patients by other previous studies [37, 38]. Based on experimental studies, up-regulation of TNF-α and IL-6 induces insulin resistance through activation of JNK and MAPK signaling pathways and consequently disrupts insulin signaling pathway leading to insulin resistance [39, 40]. As our other findings, a significant positive association between miRNA-122 and TNF-α and IL-6 was seen. Moreover, in the current study, elevated gene expression of circulating miRNA-122 was observed in T2DM patients. This finding confirms the results of earlier works indicating that the miRNA-122 expression levels can be used as a powerful biomarker in diagnosis of T2DM [41–44]. The role of T lymphocytes, a major component of the immune system, as pathogenic mediators in T2DM is well-described [45]. Valentina Manfe et al. identified miRNA-122 in advanced cutaneous T-cell lymphoma (CTCL). They also identified that enhanced expression of miRNA-122 triggers Akt phosphorylation and activation [46]. It can be shown that miRNA-122 may play a crucial role in elevated expression of inflammatory factors via Akt activation. The study also showed that miRNA-122 concentration is correlated with insulin resistance which is consistent with previous studies [44, 47]. MiRNA-122 may target PRKAB1, a subunit of AMPK, which is a key regulator of IR in muscle [47, 48]. Although the possible role of miRNA-122 in modulation of inflammatory cascades is well described, the exact mechanism through which miRNA-122 affects TNF-α and IL-6 levels consequently linked to insulin resistance in T2DM patients remains poorly understood. Future studies are needed in order to clarify the exact mechanisms of action between miRNA-122 and IL-6, and to see their precise correlation as well as the key role of miRNA-122 in the presence of inflammation in T2DM.

We found an inverse significant relation between gene expression levels of anti-inflammatory miRNA-126-3p and miRNA-146a and serum concentrations of TNF-α and IL-6; as well as HOMA-IR. In addition, the decreased gene expression levels of miRNA-126-3p and miRNA-146a were observed in both pre-diabetic and T2DM patients. These findings were in consistent with others which have reported the reduced levels of miRNA-126 in diabetic and pre-diabetic patients compared to healthy individuals, that can be used as a potential biomarker in early detection of T2DM even in patients with nephropathy and coronary artery disease [49–51]. Elevated expression of miRNA-126 as an anti-inflammatory miRNA, decreased the secretion of TNF-α as well as IL-6 in human gingival cells [52]. It has been suggested that miRNA-126 regulates inflammatory cytokines secretion through inhibiting TRAF6 and hampering NF-κB signaling pathways [53]. It seems that these observations along with the results of this study which showed a negative association between the expression of miRNA-126-3p and HOMA-IR, supports the anti-inflammatory role of miRNA-126-3p. Consistently, Noha A. Rezk et al. showed a negative, but not significant, association between serum miRNA-126
and insulin resistance [4]. Overall, it may suggest that miRNA-126 would improve the insulin resistance through regulating NF-κB signaling and secretion of inflammatory biomarkers including TNF-α and IL-6 [45]. Despite of the crucial contribution of NF-κB signaling in clarification of a link between miRNA-126 and the inflammatory cytokines release, it was not examined in the present study and future studies are needed to elucidate underlying mechanisms. In terms of miRNA-146a, our findings were in line with the findings of previous studies in which demonstrated that reduced levels of miRNA-146a were associated with insulin resistance, some pro-inflammatory cytokine genes and circulatory levels of inflammatory markers in T2DM patients [54]. However, the results of primary studies are controversial. In contrast to the findings of the present study, some studies failed to find any significant change in miRNA-146a levels [49], and another study has reported the significant increase in circulating miRNA-146a in pre-diabetics [55]. A most recent meta-analysis has concluded that gene expression of miRNA-146a in whole blood and PBMs elevates in T2DM subjects but not in serum and plasma [56]. It seems that some sex and age differences in circulating miRNAs might adjust these controversial findings [57]. Moreover, it might be due to different genetic variation in different population. We also found a negative correlation between miRNA-146a and IL-6, TNF-α, which is consistent with the findings in previous studies on other chronic and inflammatory conditions. Consistently, Kamali et al. reported an elevated expression of NF-κB (as a key activator of IL-6 and TNF-α) through miRNA-146a knockdown in human umbilical vein endothelial cells [58]. Yang et al. also reported that miRNA-146a suppression in human alveolar macrophages led to enhanced expression of IL-6 and TNF-α [59]. Cumulatively, it can be concluded that miRNA-146a negatively regulates the production of IL-6 and TNF-α. Moreover, our observation that miRNA-146a expression was negatively correlated with IR (insulin resistance) is aligned with previous studies. Balasubramanyam et al. [54] reported that reduced levels of miRNA-146a were associated with IR in Type 2 diabetic patients. Some studies have shown that miRNA-146a may reduce insulin resistance by activating JNK and P38 MAPK pathways which can play a major role in insulin signaling pathway [60, 61]. However, as we mentioned, more investigations are needed to extract the exact mechanism in this regard.

The present study has several strengths. This work was the first study that evaluated the association between three miRNAs and inflammatory factors as well as insulin resistance in T2DM, pre-diabetic and healthy individuals. Moreover, in order to minimize the variation in inflammatory status, only individuals with BMI 25–35 and non-smokers were included and all groups were matched for sex and age. However, some limitations are needed to be considered. Due to the case-control design of this study, causality cannot be inferred. In addition, we did not evaluate the effect of dietary antioxidants on inflammatory factors. Evaluating the insulin resistance by hyperinsulinemic euglycemic clamp as a gold-standard method instead of HOMA-IR index utilized in this study can help to confirm current findings. Moreover, assessing the effects of these three altered miRNAs on the expression of TNF and IL6 genes would be helpful to confirm our results. Conducting clinical trials with the larger sample size and using luciferase report assay, as a powerful tool for miRNAs target identification, can also be suggested for future studies.

Conclusions

In summary, these results showed that the expression of miRNA-122 increased in T2DM patients compared to healthy individuals. Moreover, miRNA-126-3p and miRNA-146a expression levels decreased in T2DM individuals. Additionally, a significant relationship between miRNA-122, miRNA-126-3p, miRNA-146a and inflammatory factors and insulin...
resistance were observed in this research. MiRNAs may play a crucial role in pathophysiology of T2DM through inflammatory pathways. Their implications as preventative and diagnostic biomarkers need further investigation.

Supporting information

S1 Table. The demographic characteristics of the studied groups. (DOCX)

S2 Table. Expression levels of miRNA-122, miRNA-126-3p and miRNA-146a in T2DM (n = 30), pre-diabetic (n = 30) and control group (n = 30). (DOCX)

Acknowledgments

We would like to acknowledge all the participants and members who participated in this study as well as Shahid Sadoughi university of medical sciences, Iran’s National Science Foundation (INSF) and Yazd Diabetes Research Center for their supports. We also acknowledge Dr Shima Abdollahi for her cooperation and assistance in laboratory services.

Author Contributions

Conceptualization: Fahime Zeinali, Hassan Mozaffari-Khosravi.
Data curation: Mohammad Yahya Vahidi Mehrjardi.
Formal analysis: Hossein Fallahzadeh.
Funding acquisition: Hassan Mozaffari-Khosravi.
Investigation: Fahime Zeinali, Seyed Mohsen Aghaei Zarch.
Methodology: Seyed Mehdi Kalantar.
Project administration: Masoud Rahmanian.
Resources: Hassan Mozaffari-Khosravi.
Supervision: Hassan Mozaffari-Khosravi.
Visualization: Mahdieh Hosseinzadeh.
Writing – original draft: Fahime Zeinali, Seyed Mohsen Aghaei Zarch.
Writing – review & editing: Alireza Jahan-Mihan.

References

1. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes/metabolism research and reviews. 2010; 26(3):150–171. https://doi.org/10.1002/dmrr.1068 PMID: 20222150
2. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444(7121): 840–846. https://doi.org/10.1038/nature05482 PMID: 17167471
3. Nathan DM. Long-term complications of diabetes mellitus. New England Journal of Medicine. 1993; 328 (23):1676–1685. https://doi.org/10.1056/NEJM199306103282306 PMID: 8487827
4. Rezk NA, Sabbah NA, Saad MS. Role of microRNA 126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. IUBMB life. 2016; 68(6):452–458. https://doi.org/10.1002/lub.1502 PMID: 27118517
5. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nature Reviews Endocrinology. 2013; 9(9): 513–521. https://doi.org/10.1038/nrendo.2013.86 PMID: 23629540
MiRNA-122, miRNA-126, miRNA-146a are associated with inflammation in pre-diabetes and type 2 diabetes mellitus

6. Aghaeei Zarch SM, Vahidi Mehrjardi MY, Babakhanzadeh E, Nazari M, Talebi M, Zeniall F, et al. MiR-181b Expression Levels as Molecular Biomarker for Type 2 Diabetes. Journal of Mazandaran University of Medical Sciences. 2019; 29(176):195–201. https://jmums.mazums.ac.ir/article-1-31248-en.html.

7. Bartel DP. MicroRNAs: target recognition and regulatory functions. cell. 2009; 136(2):215–233. https://doi.org/10.1016/j.cell.2009.01.021 PMID: 19167326

8. Ezzat H, Lofty AM, Atta FA, Mohamed GA, Tawfeek HM, Abdallah AM, et al. Expression of microRNA192 in type 2 diabetes mellitus relation to glycemic control, metabolic abnormalities, renal and ocular complications. American Journal of Biochemistry. 2013; 3(4):97–106. https://doi.org/10.5923/j.ajb.20130304.03

9. Fernandez-Valverde SL, Taft RJ, Mattick JS. MicroRNAs in β-cell biology, insulin resistance, diabetes and its complications. Diabetes. 2011; 60(7):1825–1831. https://doi.org/10.2337/db11-0171 PMID: 21709277

10. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. New England Journal of Medicine. 2009; 361(15):1437–1447. https://doi.org/10.1056/NEJMoa0901282

11. Weber JA, Baxter DH, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clinical chemistry. 2010; 56(11):1733–1741. https://doi.org/10.1373/clinchem.2010.147405 PMID: 20847327

12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences. 2008; 105(30):10513–10518. https://doi.org/10.1073/pnas.0804549105 PMID: 18663219

13. Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radical Biology and Medicine. 2011; 51(5):993–999. https://doi.org/10.1016/j.freeradbiomed.2011.12.005 PMID: 21633474

14. Zeinali F, Zarch SMA, Mehrjardi MYV, Kalantar SM, Jahan-Mihan A, Karimi-Nazari E, et al. Effects of synbiotic supplementation on gut microbiome, serum level of TNF-α, and expression of microRNA-126 and microRNA-146a in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomized clinical trial. Trials. 2020; 21(1):1–9. https://doi.org/10.1186/s13063-019-3906-2 PMID: 31895811

15. Sendi H, Mead I, Wan M, Mehrab-Mohseni M, Koch K, Atala A, et al. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS one. 2018; 13(7):e0200847. https://doi.org/10.1371/journal.pone.0200847 PMID: 30024933

16. Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126 regulates miR-126 expression in endothelial progenitor cells. Journal of vascular research. 2016; 53(1–2):94–104. https://doi.org/10.1159/000448713 PMID: 27673690

17. Fernandez-Valverde SL, Monteiro AW, Phillips MI, DE EO. Swimming training in rats increases cardiac MicroRNA-126 expression and angiogenesis. Medicine and science in sports and exercise. 2012; 44(8):1453–1462. https://doi.org/10.1249/MSS.0b013e31824e8a36 PMID: 22330028

18. Li Y, Zhou Q, Pei C, Liu B, Li M, Fang L, et al. Hyperglycemia and advanced glycation and products regulate miR-126 expression in endothelial progenitor cells. Journal of vascular research. 2016; 53(1–2):94–104. https://doi.org/10.1159/000448713 PMID: 27673690

19. Abou-Zeid A, Saad M, Soliman E. MicroRNA 146a Expression in Rheumatoid Arthritis: Association with Tumor Necrosis Factor–Alpha and Disease Activity. Genetic testing and molecular biomarkers. 2011; 15(11):807–812. https://doi.org/10.1089/gtmb.2011.0026 PMID: 21810022

20. Bhatt K, Lanting LL, Jia Y, Yadav S, Reddy MA, Maglinick N, et al. Anti-inflammatory role of microRNA-146a in the pathogenesis of diabetic nephropathy. Journal of the American Society of Nephrology. 2016; 27(8):2277–2288. https://doi.org/10.1681/ASN.2015010111 PMID: 26647423

21. Chen T, Li Z, Zhu W, Ge J, Zheng X, Pan X, et al. MicroRNA-146a regulates the maturation process and pro-inflamatory cytokine secretion by targeting CD40L in oxLDL-stimulated dendritic cells. FEBS letters. 2011; 585(3):567–573. https://doi.org/10.1016/j.febslet.2011.01.010 PMID: 21236257

22. Zhao Y, Lukiew WJ. Microbiome-mediated upregulation of microRNA-146a in sporadic Alzheimer's disease. Frontiers in neurology. 2018; 9:145. https://doi.org/10.3389/fneur.2018.00145 PMID: 29615954

23. Yang Z, Chen H, Shi H, Li X, Ding X, Sheng Q, et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta diabetologica. 2014; 51(5):823–831. https://doi.org/10.1007/s00592-014-0617-8 PMID: 24881880

24. Charan J, Biswas T. How to calculate sample size for different study designs in medical research Indian journal of psychological medicine. 2013; 35(2):121–126. https://doi.org/10.4103/0253-7176.116232 PMID: 24049221
25. Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care. 2019; 42(Supplement 1):S13–S28. https://doi.org/10.2337/dc19-S002 PMID: 30559228

26. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412–419. https://doi.org/10.1007/BF00280883 PMID: 3899825

27. Wang G, Wang G, Zhang X, Wang F, Song R. Isolation of high quality RNA from cereal seeds containing high levels of starch. Phytochemical Analysis. 2012; 23(2):159–163. https://doi.org/10.1002/pcaa.1337 PMID: 21739496

28. Al-Kafaji G, Al-Mahroos G, Alsayed NA, Hasan ZA, Nawaz S, Bakhiet M. Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Molecular medicine reports. 2015; 12(5):7485–7490. https://doi.org/10.3892/mmr.2015.4416 PMID: 26460159

29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. methods. 2001; 25(4):402–408. https://doi.org/10.1006/meth.2001.1262 PMID: 11846609

30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic acids research. 2001; 29(9):e45–e45. https://doi.org/10.1093/nar/29.9.e45 PMID: 11328886

31. van Rooij E. The art of microRNA research. Circulation research. 2011; 108(2):219–234. https://doi.org/10.1161/CIRCRESAHA.110.227496 PMID: 21252150

32. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice. 2010; 87(1):4–14. https://doi.org/10.1016/j.diabres.2009.10.007 PMID: 19896746

33. Hamed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA. Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World journal of diabetes. 2015; 6(4):598–612. https://doi.org/10.4239/wjd.v6.i4.598 PMID: 25987957

34. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism. 2003; 52(5):605–608. https://doi.org/10.1053/meta.2003.50096 PMID: 12759891

35. Temelkova KT, Henkel E, Koehler C, Karre K, Hanefeld M. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. 2002; 45(1):151. https://doi.org/10.1001/s125-002-8256-1 PMID: 12516255

36. Leinonen E, Hurt-Camejo E, Wiklund O, Hultén LM, Hiukka A, Taskinen M-R. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003; 166(2):387–394. https://doi.org/10.1016/s0021-9150(02)00371-4 PMID: 12535753

37. Senthilkumar GP, Anithalekshmi MS, Yasir M, Parameswaran S, muthu Packirisamy R, Bobby Z. Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic nephropathy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018; 12(1):23–26. https://doi.org/10.1016/j.dsx.2017.08.005 PMID: 28864059

38. Wegner M, Araszkiewicz A, Piorunsk a-Stolzmann M, Wierzus-Wysocka B, Zozulinska-Ziolkiewicz D. Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation. 2013; 36(3):723–728. https://doi.org/10.1007/s10753-013-9598-y PMID: 23371411

39. Shibasaki M, Takahashi K, Ito T, Cui R, Cui R, Saito Y. A PPAR agonist improves TNF-α-induced insulin resistance of adipose tissue in mice. Biochemical and biophysical research communications. 2003; 309 (2):419–424. https://doi.org/10.1016/j.bbrc.2003.07.007 PMID: 12951066

40. Rehman K, Akash MSH, Liaquat A, Kamal S, Qadir MI, Rasul A. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Critical Reviews™ in Eukaryotic Gene Expression. 2017; 27(3):229–236. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017019712 PMID: 29199608

41. Williet P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetaki A, et al. Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes. 2017; 66 (2):347–357. https://doi.org/10.2337/db16-0731 PMID: 27899485

42. Ye D, Zhang T, Lou G, Xu W, Dong F, Chen G, et al. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life sciences. 2018; 208:201–207. https://doi.org/10.1016/j.lfs.2018.07.029 PMID: 3009064

43. Pastukh N, Meerson A, Kalish D, Jabali H, Blum A. Serum miR-122 levels correlate with diabetic retinopathy. Clinical and experimental medicine. 2019; 19(2):255–260. https://doi.org/10.1007/s10238-019-00546-x PMID: 30673918
44. Wang R, Hong J, Cao Y, Shi J, Gu W, Ning G, et al. Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults. European journal of endocrinology. 2015; 172(3):291–300. https://doi.org/10.1530/EJE-14-0867 PMID: 25515554
45. Paneni F, Costantino S, Cosentino F. Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. Cardiovascular diagnosis and therapy. 2014; 4(4): 324–332. https://doi.org/10.3978/j.issn.2223-3652.2014.08.02 PMID: 25276618
46. Manfe V, Biskup E, Rosbjerg A, Kamstrup M, Skov AG, Lerche CM, et al. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PloS one. 2012; 7(1):e29541. https://doi.org/10.1371/journal.pone.0029541 PMID: 22235305
47. Shah R, Murthy V, Pacold M, Danielson K, Tanriverdi K, Larson MG, et al. Extracellular RNAs are associated with insulin resistance and metabolic phenotypes. Diabetes care. 2017; 40(4):546–553. https://doi.org/10.2337/dc16-1354 PMID: 28183786
48. Long YC, Zerath JR. AMP-activated protein kinase signaling in metabolic regulation. The Journal of clinical investigation. 2006; 116(7):1776–1783. https://doi.org/10.1172/JCI29044 PMID: 16823475
49. Zampetaki A, Kiechel S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circulation research. 2010; 107(6):810–817. https://doi.org/10.1161/CIRCRESAHA.110.226357 PMID: 20651284
50. Amr K, Abdelmawgoud H, Ali Z, Shehat a S, Raslan H. Potential value of circulating microRNA-126 and microRNA-210 as biomarkers for type 2 diabetes with coronary artery disease. British journal of biomedical science. 2018; 75(2):82–87. https://doi.org/10.1080/09674845.2017.1402404 PMID: 29452547
51. Al-Kafaji G, Al-Mahroos G, Al-Muhtaresh HA, Skrypnyk C, Sabry MA, Ramadan AR. Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: a potential blood-based biomarker. Experimental and therapeutic medicine. 2016; 12(2):815–822. https://doi.org/10.3892/etm.2016.3395 PMID: 27446281
52. Cirillo F, Lazzeroni P, Catellani C, Sartori C, Amarni S, Street ME. MicroRNAs link chronic inflammation in childhood to growth impairment and insulin-resistance. Cytokine & growth factor reviews. 2018; 39:1–18. https://doi.org/10.1016/j.cytofgfr.2017.12.004 PMID: 29398400
53. Wu Y, Song LT, Li JS, Zhu DW, Jiang SY, Deng JY. MicroRNA-126 regulates inflammatory cytokine secretion in human gingival fibroblasts under high glucose via targeting tumor necrosis factor receptor associated factor 6. Journal of periodontology. 2017; 88(11):e179–e187. https://doi.org/10.1902/jop.2017.170091 PMID: 28598262
54. Balasubramanayam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H, et al. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Molecular and cellular biochemistry. 2011; 351(1–2):197–205. https://doi.org/10.1007/s11010-011-0727-3 PMID: 21249428
55. Rong Y, Bao W, Shan Z, Liu J, Yu X, Xia S, et al. Increased microRNA-146a levels in plasma of patients with newly diagnosed type 2 diabetes mellitus. PLoS one. 2013; 8(9):e73272. https://doi.org/10.1371/journal.pone.0073272 PMID: 24023648
56. Alipoor B, Ghaedi H, Meshkani R, Torkamandi S, Safiari S, Iranpour M, et al. Association of MiR-146a expression and type 2 diabetes mellitus: a meta-analysis. International journal of molecular and cellular medicine. 2017; 6(3):156–163. https://doi.org/10.22088/acadpub.BUMS.6.3.156 PMID: 29682467
57. Mensà À, Giuliani A, Matacchione G, Gur R, Bonfigli AR, Romagnoli F, et al. Circulating miR-146a in healthy aging and type 2 diabetes: age-and gender-specific trajectories. Mechanisms of ageing and development. 2019; 180:1–10. https://doi.org/10.1016/j.mad.2019.03.001 PMID: 30880174
58. Kamali K, Salmi Korjan E, Eftekhari E, Malekzadeh K, Ghadiri Soufi F. The role of miR-146a on NF-kB expression level in human umbilical vein endothelial cells under hyperglycemic condition. Bratisl Med J. 2016; 117(7):376–380. https://doi.org/10.4149/bmj_2016_074 PMID: 27546536
59. Yang Y, Wu B-Q, Wang Y-H, Shi Y-F, Luo J-M, Ba J-H, et al. Regulatory effects of miR-155 and miR-146a on repolarization and inflammatory cytokine secretion in human alveolar macrophages in vitro. Immunoopharmacology and immunotoxicology. 2016; 38(6):502–509. https://doi.org/10.1080/08923973.2016.1248845 PMID: 27750449
60. Roos J, Enlund E, Funcke J-B, Tews D, Holzmann K, Debatin K-M, et al. miR-146a-mediated suppression of the inflammatory response in human adipocytes. Scientific reports. 2016; 6:38339. https://doi.org/10.1038/srep38339 PMID: 27922090
61. Ebrahimi R, Bahraee A, Niazipour F, Emamgholipour S, Meshkani R. The role of microRNAs in the regulation of insulin signaling pathway with respect to metabolic and mitogenic cascades: A review. Journal of cellular biochemistry. 2019; 120(12):19290–19309. https://doi.org/10.1002/jcb.29299 PMID: 31364207